NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $3.59 +0.01 (+0.28%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.60 +0.01 (+0.14%) As of 08/22/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arbutus Biopharma Stock (NASDAQ:ABUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$3.54▼$3.6650-Day Range$3.09▼$3.5952-Week Range$2.70▼$4.72Volume903,453 shsAverage Volume712,375 shsMarket Capitalization$688.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Read More Arbutus Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreABUS MarketRank™: Arbutus Biopharma scored higher than 55% of companies evaluated by MarketBeat, and ranked 479th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.39) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -12.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 8.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.50% of the float of Arbutus Biopharma has been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 4.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.50% of the float of Arbutus Biopharma has been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 4.84%, indicating that investor sentiment is improving. News and Social Media3.5 / 5News SentimentN/A News SentimentArbutus Biopharma has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.Search Interest9 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows1 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Stock News HeadlinesArbutus Biopharma Reports Strong Revenue Growth in Q2 2025August 15, 2025 | msn.comArbutus (ABUS) Q2 Revenue Surges 529%August 7, 2025 | theglobeandmail.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 6, 2025 | globenewswire.comArbutus Biopharma Corporation (ABUS) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical FocusJune 25, 2025 | globenewswire.comArbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal ProgressMay 18, 2025 | msn.comArbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $3.27 at the beginning of 2025. Since then, ABUS stock has increased by 9.8% and is now trading at $3.59. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corporation (NASDAQ:ABUS) released its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The biopharmaceutical company had revenue of $10.74 million for the quarter, compared to analyst estimates of $2.21 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 59.28% and a negative net margin of 352.24%. Who are Arbutus Biopharma's major shareholders? Top institutional investors of Arbutus Biopharma include Two Seas Capital LP (5.45%), Geode Capital Management LLC (1.90%), BlackBarn Capital Partners LP (1.36%) and Adage Capital Partners GP L.L.C. (1.34%). View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA). Company Calendar Last Earnings8/06/2025Today8/23/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABUS CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees90Year Founded2005Price Target and Rating Average Price Target for Arbutus Biopharma$5.50 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+53.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.92 million Net Margins-352.24% Pretax Margin-351.92% Return on Equity-59.28% Return on Assets-44.11% Debt Debt-to-Equity RatioN/A Current Ratio20.53 Quick Ratio20.53 Sales & Book Value Annual Sales$6.17 million Price / Sales111.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book8.35Miscellaneous Outstanding Shares191,700,000Free Float152,784,000Market Cap$688.20 million OptionableOptionable Beta0.86 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ABUS) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.